Eighteen patients experienced relapse after initial response to therapy.
Four of the six patients with positive [(18 F]FDG-PET scans after chemotherapy experienced relapse compared with just three of 75 patients with negative [(18 F]FDG-PET scans.
This difference was also highly significant for patients with previous exposure to rituximab (median, 10 months versus not reached; P <.001) and for patients who had experienced relapse before 1 year (median, 6 months versus 47 months; P <.001).
Eight patients experienced relapse, 88%% of which occurred at distant sites.
Two weeks after the start of the treatment, he experienced relapse of behavior disorder (serum NH3, 46 μg/dL).
Seven patients achieving CR subsequently experienced relapse (3 with CD19-negative disease) between 6 weeks and 8.5 months after the infusion of CTL019 cells.
However, from the subjects who returned for follow-up visits, only eight growing patients experienced relapse, a number that was too small to evaluate statistically.
As a recovering addict who has also experienced relapse, I was completely devastated by the news.
138 (59%) patients experienced relapse of ABPA with the median (range) relapses being 1 (0–7).
In order to identify potential molecular mechanisms involved in determining the site of relapse, Smid et al. [30] mapped differentially expressed genes from 107 primary breast tumors from lymph node negative patients at the time of diagnosis which experienced relapse.
None of the patients experienced relapse after these treatments.
